In a small (n=9) phase I open-label clinical trial, a 3-day oral course of dasatinib plus quercetin reduced senescent-cell markers in adipose tissue and skin of people with diabetic kidney disease.
Sources
- Is There a Cure for Aging? (webmd.com)
- https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(19)30591-2/fulltext (thelancet.com)
- https://www.alzforum.org/therapeutics/dasatinib-quercetin (alzforum.org)
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796530/ (ncbi.nlm.nih.gov)